Adalimumab Is Associated With Lower Healthcare Resource and Steroid Use Versus Vedolizumab in Biologic-Naive Crohn’s Disease: A Retrospective Claims Database Analysis

BACKGROUND: We compared real-world healthcare resource utilization (HRU), Crohn’s disease (CD)-related complications, and time to systemic corticosteroid discontinuation between patients with CD treated with adalimumab versus vedolizumab as initial biologic. METHODS: Biologic-naïve adults with CD an...

Descripción completa

Detalles Bibliográficos
Autores principales: Ungaro, Ryan C, Griffith, Jenny, Garcia-Horton, Viviana, Wang, Aolin, Cross, Raymond K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Observations and Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9434638/
https://www.ncbi.nlm.nih.gov/pubmed/36061451
http://dx.doi.org/10.1093/crocol/otac029

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9434638/
https://www.ncbi.nlm.nih.gov/pubmed/36061451
http://dx.doi.org/10.1093/crocol/otac029

Ejemplares similares